3341-41-1

Basic information

• Product Name: 1-[1-(phenylamino)cyclopentyl]ethanone
• CAS NO: 3341-41-1
• Molecular Formula: C₁₃H₁₇NO
• Molecular Weight: 203.2802
• Mol File: 3341-41-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 338.8°C at 760 mmHg
• Flash Point: 133.3°C
• Density: 1.108g/cm³
• Vapor Pressure: 9.57E-05mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: 1-[1-(phenylamino)cyclopentyl]ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[1-(phenylamino)cyclopentyl]ethanone(3341-41-1)
• EPA Substance Registry System: 1-[1-(phenylamino)cyclopentyl]ethanone(3341-41-1)

Safety Data

• Hazardous Substances Data: 3341-41-1(Hazardous Substances Data)

Usage

General Description

1-[1-(phenylamino)cyclopentyl]ethanone is a chemical compound with the molecular formula C13H15NO. It is a ketone derivative, containing a cyclopentyl group substituted with a phenylamino group and a ethanone moiety. 1-[1-(phenylamino)cyclopentyl]ethanone may have various applications in organic synthesis and pharmaceutical research due to its structural characteristics and potential reactivity. It is important to note that as with any chemical, proper handling and precautions should be taken when working with 1-[1-(phenylamino)cyclopentyl]ethanone to ensure safety and proper usage.

Upstream product

• 765-87-7 cyclohexane-1,2-dione 
• 96304-02-8 2-hydroxy-2-methylcyclohexanone 
• 62-53-3 aniline 
• 1422514-64-4 6-methyl-1,4-dioxaspiro[4.5]decan-6-ol 
• 4746-96-7 1,4-dioxaspiro[4.5]decan-6-one 

Relevant articles and documents

Improved methods for thermal rearrangement of alicyclic α-hydroxyimines to α-aminoketones: Synthesis of ketamine analogues as antisepsis candidates

Ketamine is an analgesic/anesthetic drug, which, in combination with other drugs, has been used as anesthetic for over 40 years. Ketamine induces its analgesic activities by blocking the N-methyl-D-aspartate (NMDA) receptor in the central nervous system (CNS). We have reported that low doses of ketamine administrated to patients before incision significantly reduced post-operative inflammation as reflected by reduced interleukin-6 (IL-6) sera-levels. Our data demonstrated in a rat model of Gram-negative bacterial-sepsis that if we inject a low dose of ketamine following bacterial inoculation we reduce mortality from approximately 75% to 25%. Similar to what we have observed in operated patients, the levels of TNF-α and IL-6 in ketamine-treated rats were significantly lower than in septic animals not treated with ketamine. On the base of these results, we have designed and synthesized series of new analogues of ketamine applying a thermal rearrangement of alicyclic α-hydroxyimines to α-aminoketones in parallel arrays. One of the analogues (compound 6e) displayed high activity in down-regulating the levels of IL-6 and TNF-α in vivo as compared to ketamine.